INO Inovio Pharmaceuticals Inc.

8.44
+0.7  (+9%)
Previous Close 7.74
Open 8.48
Price To Book 422
Market Cap 1,230,468,512
Shares 145,790,108
Volume 31,239,707
Short Ratio
Av. Daily Volume 35,194,956
Stock charts supplied by TradingView

NewsSee all news

  1. INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today

    PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug

  2. INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia

    PLYMOUTH MEETING, Pa., March 30, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today reported interim results from an open-label Phase 2 trial designed to evaluate the safety and efficacy of VGX-3100 in

  3. INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia

    PLYMOUTH MEETING, Pa., March 26, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced positive interim results from an open-label, Phase 2 study showing its lead DNA medicine candidate VGX-3100

  4. Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

    Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), and Inovio Pharmaceuticals Inc., (NASDAQ:INO) developing DNA medicines for infectious diseases and cancer, announced today

  5. INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results

    PLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 12-month overall survival data due June 2020, with 18-month data due 4Q 2020.
INO-5401 + cemiplimab
Glioblastoma (GBM)
Phase 1/2 trial discontinued - noted July 16, 2019.
INO-5401 and atezolizumab
Bladder cancer
Phase 1b data at ESMO 2018 noted 86% of patients remained progression-free after 72 weeks.
INO-5150
Prostate cancer
Phase 2 data due in 2020.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data due 4Q 2020.
VGX-3100 - REVEAL-1
Cervical dysplasia
Phase 2 data noted 50% showed clearance of HPV lesions and 75% showed a decrease in the number of lesions 6 months after the start of treatment - March 26, 2020.
VGX-3100
Human papilloma virus (HPV)-related anal dysplasia
Phase 2 interim data due 2020.
PENNVAX-GP
HIV
Phase 2 trial to be initiated in 2020.
INO-4700 / GLS-5300
MERS virus (Middle East Respiratory Syndrome)
Phase 2 commencement of dosing announced December 4, 2018.
MEDI0457
Human papilloma virus (HPV)
Phase 3 initiation announced March 4, 2019.
VGX-3100 - REVEAL-2
Cervical Dysplasia
Phase 1 data to be presented in 2020.
INO-4500
Lassa virus
Phase 1 trial announced July 29, 2019.
INO-5151
Castration-resistant Prostate Cancer
Phase 1 data due 2020.
INO-A002
Zika virus
Phase 2 trial to be initiated 1H 2020.
INO-3107
Recurrent respiratory papillomatosis
Phase 1 trial commenced dosing April 6, 2020.
INO-4800
Coronavirus COVID-19

Latest News

  1. INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today

    PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug

  2. INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia

    PLYMOUTH MEETING, Pa., March 30, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today reported interim results from an open-label Phase 2 trial designed to evaluate the safety and efficacy of VGX-3100 in

  3. INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia

    PLYMOUTH MEETING, Pa., March 26, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced positive interim results from an open-label, Phase 2 study showing its lead DNA medicine candidate VGX-3100

  4. Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

    Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), and Inovio Pharmaceuticals Inc., (NASDAQ:INO) developing DNA medicines for infectious diseases and cancer, announced today

  5. INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results

    PLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect

  6. INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine

    PLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate

  7. Inovio Pharmaceuticals Investors Who Have Lost Money Should Contact Block & Leviton

    BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- National securities litigation firm Block & Leviton (www.blockesq.com) is investigating potential claims against Inovio Pharmaceuticals (NASDAQ:INO) and certain of its

  8. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800

    PLYMOUTH MEETING, Pa., March 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory

  9. Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    PLYMOUTH MEETING, Pa., March 2, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that fourth quarter and full year 2019 financial results will be released after the market close on March 12,

  10. Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)

    PLYMOUTH MEETING, Pa., Feb. 10, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to

  11. Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections

    PLYMOUTH MEETING, Pa., Feb. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma

  12. Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China

    PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development in China of

  13. VGXI to Manufacture Vaccine Against Novel Coronavirus Under CEPI Funded Collaboration

    Texas-based plasmid DNA Manufacturer VGXI, Inc. to enable accelerated production of a vaccine against the 2019 novel Coronavirus in a CEPI funded collaboration. THE WOODLANDS, Texas (PRWEB) January 29, 2020 VGXI, a

  14. VGXI to Manufacture Vaccine Against Novel Coronavirus Under CEPI Funded Collaboration

    THE WOODLANDS, Texas, Jan. 29, 2020 /PRNewswire-PRWeb/ -- VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus

  15. Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial

    PLYMOUTH MEETING, Pa., Jan. 29, 2020 /PRNewswire/ -- Geneos Therapeutics announced today that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its proprietary GT-EPIC™ platform), will be evaluated in a

  16. Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

    PLYMOUTH MEETING, Pa., Jan. 23, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to

  17. Inovio Welcomes Biotech Leader to its Board of Directors

    PLYMOUTH MEETING, Pa., Jan. 15, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard to its Board of Directors. Mr. Shepard brings broad healthcare and financial

  18. BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender Community

    BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system

  19. Inovio Provides Update on Clinical Program Plans for 2020

    PLYMOUTH MEETING, Pa., Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's

  20. Inovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

    PLYMOUTH MEETING, Pa., Nov. 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Piper Jaffray 31st

  21. Inovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

    PLYMOUTH MEETING, Pa., Nov. 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Stifel 2019

  22. Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results

    PLYMOUTH MEETING, Pa., Nov. 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), an innovative biotechnology company focused on the discovery, development, and commercialization of synthetic DNA

  23. Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

    80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today

  24. Inovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

    PLYMOUTH MEETING, Pa., Oct. 29, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that third quarter 2019 financial results will be released after the market close on November 12, 2019.

  25. Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

    PLYMOUTH MEETING, Pa., Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes

  26. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences

    PLYMOUTH MEETING, Pa., Sept. 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming